Innovative immune system products

Opsona Therapeutics is developing innovative products to modulate the human immune system using a platform of small molecules and biologics.

These are all accepted and proven therapeutic approaches for the treatment of acute and chronic inflammation.

Products in development

Opsona’s current clinical lead compound, Tomaralimab (OPN-305) is at the clinical development stage and our small molecule inhibitor of IL-1β is at the discovery stage:

Clinical Development

  • Tomaralimab (OPN-305) - First in class fully humanised antibody to inhibit TLR2-mediated inflammation which is linked with the pathogenesis and progression of certain cancer conditions. Tomaralimab is now at the clinical testing phase.  Read more about Tomaralimab


Read more about partnering opportunities